Imatinib mesylate discontinuation in patients with chronic myelogenous leukaemia in complete molecular remission for more than two years.

被引：0
|
作者：
Rousselot, P
Huguet, F
Cayuela, JM
Maarek, O
Marit, G
Gluckman, E
Reiffers, J
Mahon, FX
机构：
[1] Hop St Louis, Federat Hematol, Paris, France
[2] Hop Mignot, Versailles, France
[3] Hop Purpan, Toulouse, France
[4] Hop Haut Leveque, Bordeaux, France
[5] Inst Bergonie, Bordeaux, France
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1101
引用
收藏
页码：321A / 321A
页数：1
相关论文
共 50 条
  • [1] Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
    Rousselot, Philippe
    Huguet, Francoise
    Rea, Delphine
    Legros, Laurence
    Cayuela, Jean Michel
    Maarek, Odile
    Blanchet, Odile
    Marit, Gerald
    Gluckman, Eliane
    Reiffers, Josy
    Gardembas, Martine
    Mahon, Francois-Xavier
    BLOOD, 2007, 109 (01) : 58 - 60
  • [2] Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission:: An update follow up.
    Mahon, Francois-Xavier
    Huguet, Francoise
    Etienne, Gabriel
    Réa, Delphine
    Cayuela, Jean-Michel
    Marit, Gerald
    Gardembas, Martine
    Reiffers, Josy
    Philippe, Rousselot
    BLOOD, 2006, 108 (11) : 611A - 611A
  • [3] Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?
    Stagno, Fabio
    Vigneri, Paolo
    Di Raimondo, Francesco
    LANCET ONCOLOGY, 2011, 12 (02): : 118 - 118
  • [4] Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate
    Rousselot, P
    Larghero, J
    Raffoux, E
    Calvo, F
    Tulliez, M
    Giraudier, S
    Rybojad, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (06) : 1091 - 1092
  • [5] Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
    Mahon, Francois-Xavier
    Rea, Delphine
    Guilhot, Joelle
    Guilhot, Francois
    Huguet, Francoise
    Nicolini, Franck
    Legros, Laurence
    Charbonnier, Aude
    Guerci, Agnes
    Varet, Bruno
    Etienne, Gabriel
    Reiffers, Josy
    Rousselot, Philippe
    LANCET ONCOLOGY, 2010, 11 (11): : 1029 - 1035
  • [6] Complete molecular remission in chronic myelogenous leukemia after imatinib therapy
    Barbany, G
    Höglund, M
    Simonsson, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07): : 539 - 540
  • [7] Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment
    Colombat, M
    Fort, MP
    Chollet, C
    Marit, G
    Roche, C
    Preudhomme, C
    Reiffers, J
    Praloran, V
    Mahon, FX
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (02): : 162 - 168
  • [8] Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia
    Kim, Dong-Wook
    Tan, Eugene Y.
    Jin, Yu
    Park, Sahee
    Hayes, Michael
    Demirhan, Eren
    Schran, Horst
    Wang, Yanfeng
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (02) : 199 - 206
  • [9] Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
    Bhatia, R
    Holtz, M
    Niu, N
    Gray, R
    Snyder, DS
    Sawyers, CL
    Arber, DA
    Slovak, ML
    Forman, SJ
    BLOOD, 2003, 101 (12) : 4701 - 4707
  • [10] Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy
    Bashir, Qaiser
    De Lima, Marcos J.
    McMannis, John D.
    Garcia-Manero, Guillermo
    Shpall, Elizabeth
    Kantarjian, Hagop
    Cortes, Jorge E.
    O'Brien, Susan M.
    Jones, Dan
    Qazilbash, Muzaffar
    Wei, Wei
    Giralt, Sergio A.
    Champlin, Richard E.
    Hosing, Chitra
    LEUKEMIA & LYMPHOMA, 2010, 51 (08) : 1478 - 1484
12345